SCHEMBL21241885

SCHEMBL21241885

CC(C)(C)OC(=O)NC(CCc1ccccc1)C(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.59
CTSK P43235 1/20 0.59
HDAC4 P56524 12/20 0.55
HDAC1 Q13547 11/20 0.55
HDAC2 Q92769 11/20 0.55
HDAC3 O15379 10/20 0.55
HDAC7 Q8WUI4 10/20 0.55
HDAC10 Q969S8 10/20 0.55
HDAC11 Q96DB2 10/20 0.55
HDAC8 Q9BY41 10/20 0.55
HDAC6 Q9UBN7 10/20 0.55
HDAC9 Q9UKV0 10/20 0.55
HDAC5 Q9UQL6 10/20 0.55
ELOVL1 Q9BW60 1/20 0.52
PTPRB P23467 1/20 0.49
MEF2D Q14814 2/20 0.49
SCN9A Q15858 1/20 0.49
EP300 Q09472 1/20 0.49
PARP1 P09874 1/20 0.48
ROCK2 O75116 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28522727 1.00 CTSS (0.59) CTSSCTSKHDAC4HDAC1HDAC2
SCHEMBL21224490 0.90 HDAC4 (0.57) CTSSCTSKHDAC4HDAC1HDAC2
SCHEMBL21224487 0.90 HDAC4 (0.57) CTSSCTSKHDAC4HDAC1HDAC2
SCHEMBL21224246 0.89 HDAC4 (0.54) HDAC4HDAC1HDAC2HDAC3HDAC7
SCHEMBL21224245 0.89 HDAC4 (0.54) HDAC4HDAC1HDAC2HDAC3HDAC7
SCHEMBL21224160 0.88 HDAC4 (0.60) CTSSCTSKHDAC4HDAC1HDAC2
SCHEMBL21224159 0.88 HDAC4 (0.60) CTSSCTSKHDAC4HDAC1HDAC2
SCHEMBL21225194 0.88 SCN9A (0.54) HDAC4HDAC1HDAC2HDAC3HDAC7
SCHEMBL21224256 0.88 HDAC3 (0.54) HDAC4HDAC1HDAC2HDAC3HDAC7
SCHEMBL21224257 0.88 HDAC3 (0.54) HDAC4HDAC1HDAC2HDAC3HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed
CN-112153984-A Compound and use thereof 福宏治疗公司 2020-12-29 CN disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CTSS 2010/4885CTSK 2434/4885HDAC4 152/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CTSS 2010/4885CTSK 2434/4885HDAC4 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.